NCT03655977 (RaPiCCa) is a NA clinical trial of 68Ga-NODAGA-E[c(RGDyK)]2 in Cervical Cancer, sponsored by Rigshospitalet, Denmark.

Who is sponsoring NCT03655977?

NCT03655977 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT03655977?

Interventions in NCT03655977: 68Ga-NODAGA-E[c(RGDyK)]2, PET/MRI scan instead of only MRI, 68Ga-NODAGA-E[c(RGDyK)]2, PET/MRI scan instead of only MRI.

What condition does NCT03655977 study?

NCT03655977 studies Cervical Cancer.

Is NCT03655977 still recruiting?

NCT03655977 is currently status unknown. Last updated 4 September 2018.

Last reviewed 2018-09-04 · How we verify

NCT03655977: RaPiCCa

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiation Therapy Planning by Multi-parametric PET/MRI Imaging in Patients With Cervical Cancer

Status unknown NA Last updated 4 September 2018

What this trial tests

NA trial testing 68Ga-NODAGA-E[c(RGDyK)]2 in Cervical Cancer in 25 participants. Status unknown.

Timeline

1 September 2018

Primary endpoint
1 September 2021

1 September 2021

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	25
Start date	1 September 2018
Primary completion	1 September 2021
Estimated completion	1 September 2021
Sites	1 location across Denmark

Drugs / interventions tested

68Ga-NODAGA-E[c(RGDyK)]2 — full drug profile →
PET/MRI scan instead of only MRI
68Ga-NODAGA-E[c(RGDyK)]2 — full drug profile →
PET/MRI scan instead of only MRI

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main goal of this project is to evaluate the potential and feasibility of hybrid PET/MRI functional imaging to non-invasively measure tumor characteristics for radiation therapy planning (RT) for cervical cancer. It will be assessed how the complementary information of tumor characteristics can contributed to better understanding of tumor delineation. Another endpoint of this study is to evaluate a new PET-tracer (68Ga-NODAGA- E\[c(RGDyK)\]2) enabling imaging of tumor-angiogenesis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.
Javid H, Oryani MA, Rezagholinejad N, Esparham A, et al · · 2024 · cited 137× · PMID 38349028 · DOI 10.1002/cam4.6800
Review of brachytherapy clinical trials: a cross-sectional analysis of ClinicalTrials.gov.
Chen D, Parsa R, Chauhan K, Lukovic J, et al · · 2024 · cited 2× · PMID 38351013 · DOI 10.1186/s13014-024-02415-8

Verify or expand the search:

Other trials of 68Ga-NODAGA-E[c(RGDyK)]2

Trials testing the same drug.

NCT03505346 — 68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease · Phase 2 · unknown
NCT03445884 — 68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis · Phase 2 · completed

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03655977 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 4 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03655977.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing